Natural and Medical Sciences Research Center, University of Nizwa, Nizwa, Oman.
Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, Manchester, UK.
J Immunol Res. 2022 Apr 19;2022:5545319. doi: 10.1155/2022/5545319. eCollection 2022.
Coronavirus disease 2019 (COVID-19) has been raised as a pandemic disease since December 2019. Immunosuppressive cells including T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs) are key players in immunological tolerance and immunoregulation; however, they contribute to the pathogenesis of different diseases including infections. Tregs have been shown to impair the protective role of CD8 T lymphocytes against viral infections. In COVID-19 patients, most studies reported reduction, while few other studies found elevation in Treg levels. Moreover, Tregs have a dual role, depending on the different stages of COVID-19 disease. At early stages of COVID-19, Tregs have a critical role in decreasing antiviral immune responses, and consequently reducing the viral clearance. On the other side, during late stages, Tregs reduce inflammation-induced organ damage. Therefore, inhibition of Tregs in early stages and their expansion in late stages have potentials to improve clinical outcomes. In viral infections, MDSC levels are highly increased, and they have the potential to suppress T cell proliferation and reduce viral clearance. Some subsets of MDSCs are expanded in the blood of COVID-19 patients; however, there is a controversy whether this expansion has pathogenic or protective effects in COVID-19 patients. In conclusion, further studies are required to investigate the role and function of immunosuppressive cells and their potentials as prognostic biomarkers and therapeutic targets in COVID-19 patients.
自 2019 年 12 月以来,新型冠状病毒疾病(COVID-19)已被视为一种大流行病。包括 T 调节细胞(Tregs)和髓系来源的抑制细胞(MDSCs)在内的免疫抑制细胞是免疫耐受和免疫调节的关键因素;然而,它们也导致了包括感染在内的不同疾病的发病机制。Tregs 已被证明会损害 CD8 T 淋巴细胞针对病毒感染的保护作用。在 COVID-19 患者中,大多数研究报告 Treg 水平降低,而少数其他研究发现 Treg 水平升高。此外,Tregs 具有双重作用,这取决于 COVID-19 疾病的不同阶段。在 COVID-19 的早期阶段,Tregs 在降低抗病毒免疫反应方面起着关键作用,从而减少病毒清除。另一方面,在晚期,Tregs 减少炎症引起的器官损伤。因此,在早期抑制 Tregs 并在晚期扩增 Tregs 有可能改善临床结果。在病毒感染中,MDSC 水平会大幅升高,并且它们有可能抑制 T 细胞增殖并减少病毒清除。COVID-19 患者血液中一些 MDSC 亚群扩增;然而,这种扩增在 COVID-19 患者中是否具有致病性或保护作用仍存在争议。总之,需要进一步研究来探讨免疫抑制细胞的作用和功能,以及它们作为 COVID-19 患者预后生物标志物和治疗靶点的潜力。